Search 

Formula Pharmaceuticals is a US-based oncology focused biotech company, developing Chimeric Antigen Receptor (CAR) based therapies using a proprietary platform.

Formula's CAR therapies involve allogeneic immune effector cells and a NON-viral transfection method for highly efficient cell expansion and differentiation. Additionally, Formula's target effector cells primarily involve Cytokine Induced Killer cells, instead of T-cells or Natural Killer cells. These various characteristics offer distinct practical, clinical, regulatory and commercial benefits over other CAR approaches that involve autologous cells and viral transfection methods. Although not yet in clinical stage development, Formula believes that its CAR based development program will catch up with competing clinical-stage development programs, based on the significant CMC and regulatory advantages that Formula's CAR approach offers.

Formula is interested in meeting with investors and prospective pharmaceutical/biotech partners. Near-term value driving milestones (including clinical trial results) are expected within the next 2-3 years.

Significant industry and investor interest in CAR based therapies have been established over the past 12 months, with 4 leading industry players (Pfizer; Novartis; Celgene and Juno Therapeutics). Formula's CAR therapy is distinctive, and is believed to offer significant advantages of the aforementioned CAR technologies. CARs represent a new and important paradigm for cancer therapy, with the leading pharmaceutical players expected to acquire and develop their own position into this space.

Gordian Biotechnologies addressing the urgent unmet medical existing within antibiotic resistance by developing first-in-class reversible b-lactamase inhibitors that allow existing antibiotics to be effective against otherwise resistant pathogens. By combining an FDA approved antibiotic with our novel b-lactamase inhibitors, Gordian Biotechnologies  disarms the bacteria’s resistance mechanism, allowing the antibiotic to defeat the pathogen. 

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Humabs BioMed is a profitable Swiss biotech company that is discovering and developing nature-selected human monoclonal antibodies using proprietary platforms. 

Humabs is currently focusing on the development of human antibodies to fight infectious diseases. Additional indications are being targeted at the discovery research stage.

Humabs has already achieved four major licensing deals with Pharmaceutical companies generating significant revenues in the form of near term revenues, as well as a stream of longer term milestones and royalties. Two of these programs are in clinical development phases.

Humabs is seeking additional investments to allow the company to bring selected programs into clinical research on its own, thus significantly increasing the added value.

Immunova is a startup with  an IP portfolio licensed from Yale and the Johns Hopkins Universities.

Immunova's technology platform has a unique capability to deliver one or more drugs to the tumor/disease microenvironment. The drugs can be proteins, small molecules or nucleic acids. The delivery platfrom has demonstatable advantages over other delivery systems. The technology has applications in oncology and inflammation.

The company's lead asset is positioned in oncology. IMM-01, consists of two drugs that (a) undermine the tumor micorenvironment and (b) increase anti-tumor cell mediated immunity. This asset is capable of curing mice of metastatic disease. Further, it significantly enhances the activites of immune checkpoint inhibitors. It is non toxic.

The company is seeking investment and R&D partners. Immunova has defined the path to a Phase I/IIa multidose trial which could initiate within 15 months of funding. Immunova is also seeking partners who wish to validate this platform in oncology and inflammation.

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.